Wagner F Gattaz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11228043/publications.pdf

Version: 2024-02-01

165 papers	9,866 citations	26567 56 h-index	39575 94 g-index
167 all docs	167 docs citations	167 times ranked	10473 citing authors

#	Article	IF	Citations
1	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry, 2012, 13, 318-378.	1.3	498
2	Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes. JAMA Psychiatry, 2017, 74, 143.	6.0	355
3	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World Journal of Biological Psychiatry, 2013, 14, 2-44.	1.3	343
4	Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. British Journal of Psychiatry, 2007, 190, 359-360.	1.7	323
5	Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 351-356.	1.7	319
6	Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. New England Journal of Medicine, 2017, 376, 2523-2533.	13.9	284
7	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry, 2005, 6, 132-191.	1.3	242
8	World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research, 2008, 100, 20-38.	1.1	240
9	Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry, 1987, 22, 421-426.	0.7	208
10	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry, 2006, 7, 5-40.	1.3	194
11	Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 151-163.	1.8	180
12	An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia. Psychiatry Research, 1991, 38, 125-134.	1.7	166
13	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. Journal of Psychiatric Research, 2009, 43, 978-986.	1.5	165
14	Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathologica, 2009, 117, 395-407.	3.9	146
15	Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. Journal of Neural Transmission, 2009, 116, 275-289.	1.4	137
16	Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. Journal of Psychiatric Research, 2014, 50, 36-41.	1.5	135
17	Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry, 2009, 9, 17.	1.1	133
18	Reduced Cortical Folding in Schizophrenia: An MRI Morphometric Study. American Journal of Psychiatry, 2003, 160, 1606-1613.	4.0	130

#	Article	IF	Citations
19	Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. American Journal of Psychiatry, 2005, 162, 1879-1887.	4.0	129
20	Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. Neuroscience Letters, 2011, 494, 54-56.	1.0	125
21	Does Lithium Prevent AlzheimerÊ¼s Disease?. Drugs and Aging, 2012, 29, 335-342.	1.3	122
22	Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology, 1985, 10, 187-191.	1.3	121
23	Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2013, 15, 115-121.	1.8	119
24	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	0.8	119
25	Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biological Psychiatry, 2004, 56, 41-45.	0.7	111
26	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. NeuroImage: Clinical, 2016, 12, 1-15.	1.4	107
27	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 2015, 16, 142-170.	1.3	106
28	Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophrenia Research, 2003, 61, 1-6.	1.1	104
29	Decreased phospholipase A2 activity in Alzheimer brains. Biological Psychiatry, 1995, 37, 13-17.	0.7	100
30	Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression. JAMA Psychiatry, 2018, 75, 158.	6.0	98
31	Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biological Psychiatry, 1994, 36, 137-139.	0.7	96
32	Hypofrontality on topographic EEG in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1992, 241, 328-332.	1.8	95
33	Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Medicine, 2010, 8, 89.	2.3	95
34	Effects of lithium on oxidative stress parameters in healthy subjects. Molecular Medicine Reports, 2011, 5, 680-2.	1.1	94
35	Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. European Archives of Psychiatry and Clinical Neuroscience, 1991, 241, 65-68.	1.8	91
36	Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. British Journal of Psychiatry, 2019, 215, 668-674.	1.7	91

#	Article	IF	Citations
37	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: A systematic review and meta-analysis. World Journal of Biological Psychiatry, 2014, 15, 411-418.	1.3	89
38	Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimerâ€™s disease. Journal of Psychiatric Research, 2011, 45, 220-224.	1.5	88
39	Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology, 2008, 198, 1-27.	1.5	82
40	Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry, 2010, 11, 110-120.	1.3	82
41	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 455-463.	1.2	77
42	Reduced serum levels of adiponectin in elderly patients with major depression. Journal of Psychiatric Research, 2012, 46, 1081-1085.	1.5	74
43	Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biological Psychiatry, 1985, 20, 360-366.	0.7	71
44	Long-Term, Low-Dose Lithium Treatment Does Not Impair Renal Function in the Elderly. Journal of Clinical Psychiatry, 2014, 75, e672-e678.	1.1	67
45	The deleterious effect of ocular artefacts on the quantitative EEG, and a remedy. European Archives of Psychiatry and Clinical Neuroscience, 1992, 241, 352-356.	1.8	66
46	Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophrenia Research, 2004, 66, 97-100.	1.1	65
47	Bcl-2 rs956572 Polymorphism is Associated with Increased Anterior Cingulate Cortical Glutamate in Euthymic Bipolar I Disorder. Neuropsychopharmacology, 2013, 38, 468-475.	2.8	65
48	Reduced Serum Nerve Growth Factor in Patients With Late-Life Depression. American Journal of Geriatric Psychiatry, 2013, 21, 493-496.	0.6	65
49	Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. European Neuropsychopharmacology, 2015, 25, 468-473.	0.3	65
50	Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 40-45.	0.7	64
51	Mild cognitive impairment: cognitive screening or neuropsychological assessment?. Revista Brasileira De Psiquiatria, 2008, 30, 316-321.	0.9	63
52	Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: Preliminary evidence. Psychiatry Research, 2009, 165, 1-9.	1.7	61
53	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia â€“ a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	1.2	61
54	Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology, 2009, 202, 37-51.	1.5	60

#	Article	IF	Citations
55	Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biological Psychiatry, 1991, 30, 837-840.	0.7	58
56	Circulating Glial-derived neurotrophic factor is reduced in late-life depression. Journal of Psychiatric Research, 2012, 46, 135-139.	1.5	58
57	Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophrenia Research, 2000, 43, 91-95.	1.1	57
58	Leukocyte mitochondrial DNA copy number in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 32-35.	2.5	57
59	Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. Psychiatry Research, 1983, 8, 243-250.	1.7	55
60	Differences in the immune-inflammatory profiles of unipolar and bipolar depression. Journal of Affective Disorders, 2020, 262, 8-15.	2.0	55
61	Reduced Cerebrospinal Fluid Levels of Brain-Derived Neurotrophic Factor Is Associated With Cognitive Impairment in Late-Life Major Depression. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2014, 69, 845-851.	2.4	54
62	Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology, 2005, 181, 392-400.	1.5	53
63	Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology, 2014, 231, 1315-1323.	1.5	52
64	The Short Cognitive Performance Test (SKT): a preliminary study of its psychometric properties in Brazil. International Psychogeriatrics, 2006, 18, 121-133.	0.6	51
65	Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology, 2015, 232, 245-250.	1.5	51
66	Glutamate in schizophrenics and healthy controls. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1982, 231, 221-225.	0.6	50
67	A Longitudinal (6-week) 3T 1H-MRS Study on the Effects of Lithium Treatment on Anterior Cingulate Cortex Metabolites in Bipolar Depression. European Neuropsychopharmacology, 2015, 25, 2311-2317.	0.3	50
68	Abnormal APP processing in platelets of patients with Alzheimerâ€™s disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology, 2007, 192, 547-553.	1.5	49
69	Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Revista Brasileira De Psiquiatria, 2010, 32, 216-222.	0.9	49
70	HLA antigens and schizophrenia: A pool of two studies. Psychiatry Research, 1981, 5, 123-128.	1.7	48
71	Lithium increases platelet serine-9 phosphorylated GSK-3Î² levels in drug-free bipolar disorder during depressive episodes. Journal of Psychiatric Research, 2015, 62, 78-83.	1.5	47
72	Reduced phospholipid breakdown in Alzheimerâ€™s brains: a 31P spectroscopy study. Psychopharmacology, 2005, 180, 359-365.	1.5	45

#	Article	IF	Citations
73	Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 55, 109-113.	1.0	44
74	BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: A systematic review and meta-analysis. World Journal of Biological Psychiatry, 2015, 16, 114-122.	1.3	44
75	Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 815-819.	1.4	43
76	Mild cognitive impairment (part 1): clinical characteristics and predictors of dementia. Revista Brasileira De Psiquiatria, 2013, 35, 178-185.	0.9	42
77	BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: Results from a factorial, randomized, sham-controlled trial. European Neuropsychopharmacology, 2014, 24, 1144-1151.	0.3	42
78	Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 211-217.	2.5	40
79	Lack of association between schizophrenia and the phospholipase-A2 genes cPLA2 and sPLA2. American Journal of Medical Genetics Part A, 2001, 105, 246-249.	2.4	38
80	Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukotrienes and Essential Fatty Acids, 2007, 76, 47-55.	1.0	38
81	Longâ€term lithium treatment increases intracellular and extracellular brainâ€derived neurotrophic factor (<scp>BDNF</scp>) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar Disorders, 2016, 18, 692-695.	1.1	33
82	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	1.3	33
83	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 91-96.	2.5	32
84	Cognitive impairment in lateâ€life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Bipolar Disorders, 2016, 18, 63-70.	1.1	32
85	Transcranial direct current stimulation (tDCS) for preventing major depressive disorder relapse: Results of a 6-month follow-up. Depression and Anxiety, 2019, 36, 262-268.	2.0	31
86	Basal ganglia abnormalities in tardive dyskinesia. European Archives of Psychiatry and Clinical Neuroscience, 1994, 244, 272-277.	1.8	30
87	Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 340-343.	1.8	30
88	Differential roles of phospholipases A2 in neuronal death and neurogenesis: Implications for Alzheimer disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1381-1389.	2.5	29
89	Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 243-246.	2.5	27
90	Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimerâ€™s disease: a 4-year follow-up study. Journal of Neural Transmission, 2014, 121, 193-200.	1.4	26

#	Article	IF	Citations
91	Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Human Psychopharmacology, 2015, 30, 52-56.	0.7	26
92	Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1982, 232, 463-471.	0.6	25
93	Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukotrienes and Essential Fatty Acids, 2008, 78, 265-269.	1.0	25
94	Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. Journal of Psychiatric Research, 2014, 55, 96-100.	1.5	24
95	Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial. Journal of Affective Disorders, 2015, 185, 209-213.	2.0	24
96	Rightward cerebral asymmetry in subtypes of schizophrenia according to Leonhard's classification and to DSM-IV: a structural MRI study. Psychiatry Research - Neuroimaging, 2003, 123, 65-79.	0.9	23
97	CT scans and neuroleptic response in schizophrenia: A multidimensional approach. Psychiatry Research, 1988, 26, 293-303.	1.7	22
98	Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein. Journal of Neural Transmission, 2011, 118, 1273-1279.	1.4	22
99	Early improvement with lithium in classic mania and its association with later response. Journal of Affective Disorders, 2013, 144, 160-164.	2.0	22
100	Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue. Journal of Neural Transmission, 2015, 122, 1371-1380.	1.4	22
101	Inhibition of phospholipase A2 in rat brain modifies different membrane fluidity parameters in opposite ways. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1612-1617.	2.5	21
102	Increased PLA2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis. Journal of Psychiatric Research, 2011, 45, 1617-1620.	1.5	20
103	Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. Journal of Psychiatric Research, 2012, 46, 1053-1058.	1.5	20
104	The HLA system and schizophrenia. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1980, 228, 205-211.	0.6	19
105	Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. Journal of Neural Transmission, 2013, 120, 187-195.	1.4	19
106	Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype. Clinics, 2013, 68, 277-280.	0.6	19
107	Long-Term Lithium Treatment Reduces Glucose Metabolism in the Cerebellum and Hippocampus of Nondemented Older Adults: An [¹⁸F]FDG-PET Study. ACS Chemical Neuroscience, 2014, 5, 484-489.	1.7	19
108	Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study. Experimental and Therapeutic Medicine, 2014, 8, 1205-1208.	0.8	19

#	Article	IF	Citations
109	Lithium Distinctly Modulates the Secretion of Pro- and Anti- Inflammatory Interleukins in Co-Cultures of Neurons and Glial Cells at Therapeutic and Sub-Therapeutic Concentrations. Current Alzheimer Research, 2016, 13, 848-852.	0.7	19
110	Nogo CAA 3â€²UTR Insertion polymorphism is not associated with Schizophrenia nor with bipolar disorder. Schizophrenia Research, 2005, 75, 5-9.	1.1	18
111	Hippocampal serotonin depletion is related to the presence of generalized tonicâ€“clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy. Epilepsy Research, 2015, 111, 18-25.	0.8	18
112	Bimodal Effect of Lithium Plasma Levels on Hippocampal Glutamate Concentrations in Bipolar II Depression: A Pilot Study. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	18
113	Plasma lipids metabolism in mild cognitive impairment and Alzheimerâ€™s disease. World Journal of Biological Psychiatry, 2019, 20, 190-196.	1.3	18
114	Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. International Journal of Psychophysiology, 2002, 45, 227-240.	0.5	16
115	Does BDNF genotype influence creative output in bipolar I manic patients?. Journal of Affective Disorders, 2012, 139, 181-186.	2.0	16
116	HLA-B27 as a possible genetic marker of psychoticism. Personality and Individual Differences, 1981, 2, 57-60.	1.6	15
117	Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. Biological Psychiatry, 1989, 25, 247-255.	0.7	15
118	Analysis of coding-polymorphisms in NOTCH-related genes reveals NUMBL poly-glutamine repeat to be associated with schizophrenia in Brazilian and Danish subjects. Schizophrenia Research, 2006, 88, 275-282.	1.1	15
119	Inhibition of phospholipase A2 increases Tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukotrienes and Essential Fatty Acids, 2010, 82, 57-60.	1.0	15
120	Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimerâ€™s disease patients. Revista De Psiquiatria Clinica, 2019, 46, 120-124.	0.6	15
121	Stereological investigation of the CA1 pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. Annals of Anatomy, 2017, 209, 51-60.	1.0	14
122	Bromocriptine in the treatment of neuroleptic-resistant schizophrenia. Biological Psychiatry, 1986, 21, 519-521.	0.7	13
123	Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: Possible implications for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1995, 246, 13-16.	1.8	13
124	Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimerâ€™s disease patients. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 501-507.	1.8	13
125	Cognitive changes after tDCS and escitalopram treatment in major depressive disorder: Results from the placebo-controlled ELECT-TDCS trial. Journal of Affective Disorders, 2020, 263, 344-352.	2.0	13
126	Assessment of tardive dyskinesia by means of digital image processing. Psychopharmacology, 1993, 111, 278-284.	1.5	12

#	Article	IF	Citations
127	Regulation of leukocyte tricarboxylic acid cycle in drug-naÃ¯ve Bipolar Disorder. Neuroscience Letters, 2015, 605, 65-68.	1.0	12
128	A possible association between HLA B-27 and vulnerability to schizophrenia. Personality and Individual Differences, 1985, 6, 283-285.	1.6	11
129	The generators of slow potentials obtained during verbal, pictorial and spatial tasks. International Journal of Psychophysiology, 2003, 48, 55-65.	0.5	11
130	Complex slow potential generators in a simplified attention paradigm. International Journal of Psychophysiology, 2006, 61, 149-157.	0.5	11
131	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. Schizophrenia Research, 2016, 177, 67-69.	1.1	11
132	Phospholipase A2 in Schizophrenia. Biological Psychiatry, 1992, 31, 214-216.	0.7	10
133	A radioenzymatic assay to identify three groups of phospholipase A2 in platelets. Prostaglandins Leukotrienes and Essential Fatty Acids, 2012, 86, 149-153.	1.0	10
134	Reduced activities of phospholipases A₂ in platelets of drugâ€naÃ¯ve bipolar disorder patients. Bipolar Disorders, 2015, 17, 97-101.	1.1	10
135	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimerâ€™s disease: a pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 483-488.	1.8	10
136	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: An updated systematic review and meta-analysis. World Journal of Biological Psychiatry, 2023, 24, 24-33.	1.3	10
137	Diretrizes da FederaÃ§Ã£o Mundial das Sociedades de Psiquiatria BiolÃ³gica para o tratamento biolÃ³gico da esquizofrenia. Parte 1: tratamento agudo. Revista De Psiquiatria Clinica, 2006, 33, 7-64.	0.6	9
138	Inhibition of cPLA₂and sPLA₂Activities in Primary Cultures of Rat Cortical Neurons byCentella asiaticaWater Extract. Natural Product Communications, 2012, 7, 1934578X1200700.	0.2	9
139	Reduced Annexin A3 in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 489-494.	1.8	9
140	Widespread electrical cortical dysfunction in schizophrenia. Schizophrenia Research, 2004, 69, 255-266.	1.1	8
141	Glycogen synthase kinaseâ€3Î² in patients with bipolar I disorder: results from a prospective study. Bipolar Disorders, 2016, 18, 334-341.	1.1	8
142	Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 607-618.	1.8	8
143	Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. Psychiatry Research, 1995, 58, 165-169.	1.7	7
144	Correlation between platelet and brain PLA2 activity. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 265-268.	1.0	7

#	Article	IF	Citations
145	Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial. Schizophrenia Research, 2021, 235, 44-51.	1.1	7
146	Exploring the knowledge contained in neuroimages: Statistical discriminant analysis and automatic segmentation of the most significant changes. Artificial Intelligence in Medicine, 2010, 49, 105-115.	3.8	6
147	Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia. Clinics, 2010, 65, 539-546.	0.6	6
148	Genetic polymorphisms of the 5HT receptors are not related with depression in temporal lobe epilepsy caused by hippocampal sclerosis. Epilepsy and Behavior, 2018, 83, 181-185.	0.9	6
149	Plasma metabolites in first episode psychoses. Schizophrenia Research, 2019, 206, 468-470.	1.1	6
150	NeuroquÃ¬mica da esquizofrenia: papel dos fosfolÃpides. Revista Brasileira De Psiquiatria, 2000, 22, 5-8.	0.9	5
151	Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus. Journal of Neural Transmission, 2014, 121, 695-706.	1.4	4
152	Increased platelet glycogen sysnthase kinase 3beta in first-episode psychosis. Schizophrenia Research, 2018, 195, 402-405.	1.1	4
153	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. Journal of Affective Disorders, 2022, 308, 71-75.	2.0	4
154	Chronic inhibition of brain phospholipase A2 in adult rats impairs the survival of newborn mature neurons in the hippocampus. Journal of Neural Transmission, 2015, 122, 619-628.	1.4	3
155	Antipsychotics preserve telomere length in peripheral blood mononuclear cells after acute oxidative stress injury. Neural Regeneration Research, 2022, 17, 1156.	1.6	3
156	Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity. European Archives of Psychiatry and Clinical Neuroscience, 1996, 246, 71-77.	1.8	2
157	Increased PLA2 activity in individuals at ultra-high risk for psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1593-1599.	1.8	2
158	COX-2 pathway is upregulated in ultra-high risk individuals for psychosis. World Journal of Biological Psychiatry, 2022, 23, 236-241.	1.3	2
159	HLA-Antigens, Schizophrenia and Brain Atrophy. British Journal of Psychiatry, 1980, 137, 398-399.	1.7	2
160	Lithium increases cortical and subcortical volumes in subjects with bipolar disorder. Psychiatry Research - Neuroimaging, 2022, 324, 111494.	0.9	2
161	What Does Proteomics Tell Us About Schizophrenia?. , 2011, , 345-366.		1
162	Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients. Advances in Biological Psychiatry, 2014, , 1-1.	0.2	0

#	Article	IF	Citations
163	Genetic polymorphisms of the serotonin transporter are not related with depression in temporal lobe epilepsy caused by hippocampal sclerosis. Epilepsy and Behavior, 2021, 117, 107854.	0.9	0
164	Genetic and Proteomic Studies in Schizophrenia. , 2010, , 193-218.		0
165	CSF Studies in Schizophrenia: A Multidimensional Approach. , 1985, , 144-153.		0